Q2 2024 Earnings Summary
Reported on Aug 7, 2024 (After Market Close)
Pre-Earnings Price$2.88Last close (Aug 7, 2024)
Post-Earnings Price$3.45Open (Aug 8, 2024)
Price Change
$0.57(+19.79%)
- Robust clinical data supporting reimbursement: Management highlighted multiple strong data sets and ongoing publications in breast, lung, and IO therapy monitoring that are expected to underpin Medicare reimbursement submissions, potentially unlocking higher pricing and margins.
- Scalable commercialization through strategic partnerships: The controlled ramp-up of Tempus’ sales force—with built-in volume gating—demonstrates an efficient, risk-mitigated pathway to scale NeXT Personal adoption while managing test costs and reimbursement challenges.
- Expanding biopharma relationships and pipeline growth: Continued collaboration with key partners like Moderna in Phase III trials provides a significant revenue tailwind and signals broader adoption of Personalis' platforms in clinical trials and personalized cancer therapies.
Research analysts covering Personalis.